Table 1.
Evaluation of different linkers to promote cross-presentation of the aSLP MELOE-113-27 xxxx MELOE-136-44.
| |
MELOE-113-27 xxxx MELOE-136-44 |
|
|
|---|---|---|---|
| code | Sequence | EC50 ratioa | Nb |
| P13 | ----- GGGG ----- | <0,1 | 5 |
| P15 | ----- LLSV ----- | 6–14 | 5 |
| P28 | ----- VLSVG ----- | 3–13 | 2 |
| P43 | ----- LLSVG ----- | 10–20 | 3 |
| P37 | ----- PLSVII ----- | 2.3–10 | 2 |
| P40 | ----- LLSVGG ----- | 12–56 | 3 |
| P25 | ----- VLSVGG ----- | 1.5–2 | 2 |
| P32 | ----- GLSVGG ----- | 1 | 2 |
| P33 | ----- GLSVVV ----- | 1 | 2 |
| P34 | ----- SLSVAA ----- | 7–8 | 2 |
| P35 | ----- SLSVGG ----- | 1–8 | 3 |
| P36 | ----- ALSVGG ----- | 1–3 | 2 |
aRange of EC50 ratio defined as EC50 of MELOE-111-46/EC50 of aSLP.
EC50 were determined by the TNFα response curves of a MELOE-111-46 specific CD8 T cell clone to SLP-loaded DC.
bNumber of independent experiments.